Cargando…
CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth
BACKGROUND: Loss of CD9 expression has been correlated with a higher motility and metastatic potential of tumour cells originating from different organs. However, the mechanism underlying this loss is not yet understood. METHODS: We produced a truncated form of partner 1 of CD9 (CD9P-1), GS-168AT2,...
Autores principales: | Guilmain, W, Colin, S, Legrand, E, Vannier, J P, Steverlynck, C, Bongaerts, M, Vasse, M, Al-Mahmood, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049554/ https://www.ncbi.nlm.nih.gov/pubmed/21206492 http://dx.doi.org/10.1038/sj.bjc.6606033 |
Ejemplares similares
-
A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth
por: Colin, S, et al.
Publicado: (2011) -
miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells
por: Higashi, T, et al.
Publicado: (2015) -
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma
por: Han, S, et al.
Publicado: (2014) -
Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia
por: Nankivell, P, et al.
Publicado: (2013) -
CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence
por: Hirata, K, et al.
Publicado: (2013)